Risks were high for people with chronic kidney disease or significant frailty. Odds of hip fracture remained high after ...

Researchers have identified a protein, TMEM16F, that appears to aid the spread of Parkinson’s pathology in the brain.

Cambridge, USA-based Vesalius Therapeutics has entered into a multi-target strategic alliance with the UK’s GSK to discover ...

A team of researchers from the University of Barcelona and the Bellvitge Biomedical Research Institute (IDIBELL) has identified a potential biomarker of Parkinson's disease progression.

Researchers at Tel Aviv University (TAU) discovered a new factor in the pathology of Parkinson's disease, which in the future ...

Under deal terms, GSK will give Vesalius Therapeutics $80 million in upfront and equity payments to identify treatments for ...

Analysis suggests that the research and development of DMTs and non-motor therapies will diversify Parkinson's treatment ...

GSK has licensed a small molecule for Parkinson's and is teaming up on additional targets for the disease and another ...

GSK Plc agreed on a partnership deal worth as much as $650 million with US biotech Vesalius Therapeutics to help advance drug ...

GSK is paying $80 million to ink a multi-target neurodegenerative pact with Flagship-founded Vesalius Therapeutics that ...